NEW YORK (GenomeWeb) – Nanostring Technologies today announced that its Prosigna Breast Cancer Assay has been acknowledged within the treatment guidelines of the German Association of Gynecological Oncology (AGO).

The company also said that a recent decision by the German Joint Federal Committee (G-BA) has qualified German breast cancer patients with statutory government insurance as eligible for coverage for gene expression testing, such as that provided by Prosigna, to inform therapy decisions beginning April 1.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.